Role of urinary podocalyxin in early diagnosis of diabetic nephropathy

Kostovska, Irena; Trajkovska, Katerina Tosheska; Cekovska, Svetlana; Topuzovska, Sonja; Kavrakova, Julijana Brezovska; Spasovski, Goce; Kostovski, Ognen; Labudovic, Danica

doi:10.2478/rjim-2020-0023

Abstract

Introduction. Podocyte injury has been reported as an early feature of DN therefore, the assessment of podocyte injury can be accomplished by estimation of podocalyxin in urine. This study aimed to estimate the urinary podocalyxin levels and to determine the sensitivity and specificity of this biomarker for early detection of DN.

Materials and methods. A total of 90 patients with type 2 diabetes mellitus (T2DM) were included in this cross-sectional study. Sixty of them were without diagnosed DN, and 30 with diagnosed DN. A control group consisted of 30 healthy subjects. All patients with T2DM were divided into three subgroups according to urinary microalbumin/creatinine ratio (UM/CR): normoalbuminuric, microalbuminuric and macroalbuminuric patients. Urine samples, were used for measurement of podocalyxin by ELISA, creatinine and microalbumin. Fasting venous blood samples was collected for biochemical analyses.

Results. The levels of urinary podocalyxin (u-PDX) were higher in patients with T2DM compared to control subjects and a statistically significant difference among studied subgroups regarding u-PDX was found (p < 0.05). Levels of u-PDX are increasing gradually with the degree of DN (p < 0.029). u-PDX levels were positively correlated with UM/CR (r = 0.227, p = 0.002). A cut-off level of 43.8 ng/ml u-PDX showed 73.3% sensitivity and 93.3% specificity to detect DN in early stage. A cut-off level of 30 mg/g UM/CR showed 41.5% sensitivity and 90% specificity in predicting DN. u-PDX was elevated in 48,2% of normoalbuminuric patients.

Conclusion. Urinary podocalyxin be useful and more sensitive and specific marker in early detection of DN than microalbuminuria.

References

1. UMANATH K., LEWIS JB., Update on Diabetic Nephropathy: Core Curriculum 2018, Am. J. Kidney. Dis., 2018, 71(6):884–895.
Search in Google Scholar Back to article
2. PUGLIESE G., PENNO G., NATALI A., BARUTTA F., DI PAOLO S., REBOLDI G. et al., Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”, J. Nephrol., 2020, 33(1):9–35.
Search in Google Scholar Back to article
3. PERSSON F., ROSSING P., Diagnosis of diabetic kidney disease: state of the art and future perspective, Kidney. Int. Suppl (2011), 2018, 8(1):2–7.
Search in Google Scholar Back to article
4. UWAEZUOKE SN., The role of novel biomarkers in predicting diabetic nephropathy: a review, Int. J. Nephrol. Renovasc. Dis., 2017, 10:221–231.10.2147/IJNRD.S143186556636728860837
Search in Google Scholar Back to article
5. LEE SY., CHOI ME., Urinary biomarkers for early diabetic nephropathy: beyond albuminuria, Pediatr. Nephrol., 2015, 30(7):1063–1075.
Search in Google Scholar Back to article
6. DAI H., LIU Q., LIU B., Research Progress on Mechanism of Podocyte Depletion in Diabetic Nephropathy., J. Diabetes. Res., 2017, 2017:2615286.10.1155/2017/2615286553429428791309
Search in Google Scholar Back to article
7. LIAPIS H., ROMAGNANI P., ANDERS HJ., New insights into the pathology of podocyte loss: mitotic catastrophe., Am. J. Pathol. 2013, 183(5):1364–1374.
Search in Google Scholar Back to article
8. MATOVINOVIC MS., 3. Podocyte Injury in Glomerular Diseases., EJIFCC, 2009, 20(1):21–27.
Search in Google Scholar Back to article
9. NAKAMURA T., USHIYAMA C., SUZUKI S., HARA M., SHIMADA N.,EBIHARA I. et al., Urinary excretion of podocytes in patients with diabetic nephropathy, Nephrol. Dial. Transplant., 2000, 15:1379–1383.10.1093/ndt/15.9.137910978394
Search in Google Scholar Back to article
10. WEIL EJ., LEMLEY KV., MASON CC., YEE B., JONES LI., BLOUCH K. et al., Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy, Kidney. Int., 2012, 82(9):1010–1017.
Search in Google Scholar Back to article
11. FISHEA T., Urinary biomarkers for early diabetic nephropathy in type 2 diabetic patients, Biomark. Res., 2015, 3:16.10.1186/s40364-015-0042-3449123926146561
Search in Google Scholar Back to article
12. NAUTA FL., BOERTIEN WE., BAKKER SJL., GOOR HV., OEVEREN WV., YONG PE. et al., Glomerular and tubular damage markers are elevated in patients with diabetes, Diabetes. Care., 2011, 34:975–981.10.2337/dc10-1545306406021307379
Search in Google Scholar Back to article
13. KANDASAMY Y., SMITH R., LUMBERS ER., RUDD D., Nephrin – a biomarker of early glomerular injury, Biomark. Res., 2014, 2:21.10.1186/2050-7771-2-21436319225789166
Search in Google Scholar Back to article
14. SEKULIC M., SEKULIC PS., A compendium of urinary biomarkers indicative of glomerular podocytopathy, Pathol. Res. Int., 2013, 2013:782395.10.1155/2013/782395384533624327929
Search in Google Scholar Back to article
15. GLUHOVSCHI C., GLUHOVSCHI G., PETRICA L., TIMAR R., VELCIOV S., IONITA I. et al., Urinary Biomarkers in the Assessment of Early Diabetic Nephropathy, J. Diabetes. Res., 2016, 2016:4626125.10.1155/2016/4626125492799027413755
Search in Google Scholar Back to article
16. REISER J., ALTINTAS MM., Podocytes, F1000Res, 2016, 5:F1000 Faculty Rev-114.10.12688/f1000research.7255.1475540126918173
Search in Google Scholar Back to article
17. NIELSEN J., MCNAGNY K., The Role of Podocalyxin in Health and Disease, J. Am. Soc. Nephrol., 2009, 20(8):1669–1676.
Search in Google Scholar Back to article
18. KOSTOVSKA I., TRAJKOVSKA TK., CEKOVSKA S., SPASOVSKI G., LABUDOVIC D., Nephrin and Podocalyxin – New Podocyte Proteins for Early Detection of Secondary Nephropathies, BANTAO J., 2016, 14(1):11–16.
Search in Google Scholar Back to article
19. SUN D., ZHAO X., MENG L., Relationship between urinary podocytes and kidney diseases, Ren. Fail. 2012, 34(3):403–407.10.3109/0886022X.2011.64962722250862
Search in Google Scholar Back to article
20. AGARWAL R., Diabetic nephropathy, proteinuria, and progression of CKD, Clin. J. Am. Soc. Nephrol., 2009, 4:1523–1528.10.2215/CJN.0201030919478099
Search in Google Scholar Back to article
21. KDIGO., Chapter 1: Definition and classification of CKD, Kidney. Int. Suppl., 2013, 3:19.10.1038/kisup.2012.64408969325018975
Search in Google Scholar Back to article
22. COCKROFT DW., GAULT MH., Prediction of creatinine clearance from serum creatinine, Nephron., 1976, 16:31–41.10.1159/0001805801244564
Search in Google Scholar Back to article
23. NAVRA AS., BILOUS RW., Laboratory Assessment of Diabetic Kidney Disease, Diabetes. Spectr., 2015, 28(3):162–166.
Search in Google Scholar Back to article
24. ŠIMUNDIC AM., Measures of Diagnostic Accuracy: Basic Definitions, EJIFCC., 2009, 19(4):203–211.
Search in Google Scholar Back to article
25. HABIBZADEH F., HABIBZADEH P., YADOLLAHIE M., On determining the most appropriate test cut-off value: the case of tests with continuous results, Biochem. Med., 2016, 26(3):297–307.
Search in Google Scholar Back to article
26. CHIDA S., FUJITA Y., OGAWA A., HAYASHI A., ICHIKAWA R., HAYASHI A. et al., Levels of albuminuria and risk of developing macroalbuminuria in type 2 diabetes: historical cohort study, Sci. Rep., 2016, 6:26380.10.1038/srep26380487647527210499
Search in Google Scholar Back to article
27. El-SAEED GK., SHEHAB El-DEEN WA., MONTASR BA., OMAR TA., MOHAMED DS., Urinary podocalyxin and cyclophilin A: markers for early detection of type 2 diabetic nephropathy, Menoufia. Med. J., 2019, 32:996–1003.10.4103/mmj.mmj_223_18
Search in Google Scholar Back to article
28. Al-RUBEAAN K., SIDDIQUI K., Al-GHONAIM MA., YOUSSEF AM., Al-SHARQAWI AH., AlNAQEB D., Assessment of the diagnostic value of different biomarkers in relation to various stages of diabetic nephropathy in type 2 diabetic patients, Sci. Rep., 2017, 7(1):2684.
Search in Google Scholar Back to article
29. YE H., BAI X., GAO H., LI L., WU C., SUN X. et al., Urinary podocalyxin positive-element occurs in the early stage of diabetic nephropathy and is correlated with a clinical diagnosis of diabetic nephropathy, J. Diabetes. Complicat., 2014, 28:96–100.10.1016/j.jdiacomp.2013.08.00624075693
Search in Google Scholar Back to article
30. HARA M., YAMAGATA K., TOMINO Y., SAITO A., HIRAYAMA Y., OGASAWARA S. et al., Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin, Diabetologia., 2012, 55(11):2913–2919.10.1007/s00125-012-2661-7346437122854890
Search in Google Scholar Back to article
31. SHOJI M., KOBAYASHI K., TAKEMOTO M., SATO Y., YOKOTE K., Urinary podocalyxin levels were associated with urinary albumin levels among patients with diabete, Biomarkers., 2016, 21(2):164–167.
Search in Google Scholar Back to article
32. WANG R.,YAO C., LIU F., Association between Renal Podocalyxin Expression and Renal Dysfunction in Patients with Diabetic Nephropathy: A Single-Center, Retrospective Case-Control Study, BioMed. Res. Int., 2020, Article ID 7350781.10.1155/2020/7350781715779032337271
Search in Google Scholar Back to article
33. BACCI MR., CHEHTER EZ., AZZALIS LA, COSTA DE AGUIAR ALVES B., FONCESKA FLA., Serum NGAL and Cystatin C Comparison With Urinary Albumin-to-Creatinine Ratio and Inflammatory Biomarkers as Early Predictors of Renal Dysfunction in Patients With Type 2 Diabetes, Kidney. Int. Rep., 2016, 2(2):152–158.
Search in Google Scholar Back to article

Role of urinary podocalyxin in early diagnosis of diabetic nephropathy

Abstract

Paradigm

My account